Editas Medicine (EDIT) Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings or view top-rated stocks.

13 brokerages have issued 1-year price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they expect the company's stock price to reach $15.86 in the next twelve months. This suggests a possible upside of 74.3% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.

Editas Medicine's stock was trading at $8.87 at the beginning of the year. Since then, EDIT shares have increased by 2.6% and is now trading at $9.10.
View the best growth stocks for 2023 here.

Editas Medicine saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 20,230,000 shares, an increase of 7.3% from the April 30th total of 18,860,000 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is presently 11.0 days.
View Editas Medicine's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our EDIT earnings forecast.

Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Friday, May, 5th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.08. The firm had revenue of $9.90 million for the quarter, compared to analysts' expectations of $3.29 million. Editas Medicine had a negative trailing twelve-month return on equity of 56.20% and a negative net margin of 960.70%. The company's revenue for the quarter was up 45.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.74) EPS.

ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Horizon Kinetics Medical ETF (MEDX), AXS Green Alpha ETF (NXTE), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (11.83%), BlackRock Inc. (10.75%), Dimensional Fund Advisors LP (2.34%), Geode Capital Management LLC (2.10%), JPMorgan Chase & Co. (1.64%) and Pictet Asset Management SA (1.53%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EDIT stock can currently be purchased for approximately $9.10.

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $627.90 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis.

The company employs 264 workers across the globe.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.